rs6887695 — IL12B Upstream regulatory

IL12B Upstream Regulatory Variant — Core of the Psoriasis Risk Haplotype

The IL12B gene¹¹ IL12B gene
located at chromosome 5q33.3, encodes the 40 kDa p40 subunit shared by two functionally distinct cytokines: IL-12 (p40/p35 heterodimer) and IL-23 (p40/p19 heterodimer). IL-12 drives Th1 differentiation, IFN-γ production, and antimicrobial immunity; IL-23 expands Th17 cells and IL-17 production, sustaining chronic skin and gut inflammation. Both pathways converge on psoriatic disease — IL-12/Th1 activates keratinocytes via IFN-γ, while IL-23/Th17 drives the epidermal hyperproliferation and neutrophil recruitment that characterise psoriatic plaques. rs6887695 lies approximately 60 kilobases upstream of the IL12B coding region at chr5:159,395,637 (GRCh38), in a non-coding upstream regulatory region that modulates IL12B transcriptional output. Together with rs3212227 in the 3'-untranslated region of IL12B, it defines the canonical IL12B psoriasis risk haplotype²² canonical IL12B psoriasis risk haplotype
the two SNPs tag a regulatory state of the IL12B locus associated with elevated p40 expression and stronger Th1/Th17 immune activation.

The Mechanism

rs6887695 is a G>C substitution on the plus strand (forward orientation, GRCh38). The C allele is the risk-conferring allele, tagging a regulatory configuration of the IL12B locus that promotes higher p40 expression. Functional studies of the risk haplotype defined by rs6887695-C and rs3212227-A demonstrate that homozygous risk carriers show 12.5-fold higher IL12B mRNA expression after stimulation³³ homozygous risk carriers show 12.5-fold higher IL12B mRNA expression after stimulation
Johnston et al. 2013, 202 affected individuals vs 17 non-carriers; Th1 cytokine milieu markedly amplified compared to non-carriers, alongside approximately 6-fold elevated serum IL-12 levels and enhanced IFN-γ responses. Paradoxically, this Th1-dominant milieu suppresses IL-23/Th17 activation, which explains why psoriatic skin in risk haplotype carriers can show unexpectedly strong IFN-γ signatures. The net effect of elevated p40 is higher sustained production of both IL-12 and IL-23, fuelling the chronic immune dysregulation that underlies psoriatic disease, inflammatory bowel disease, and related autoimmune conditions where the IL-12/23 axis is therapeutic target.

The Evidence

The strongest European data come from Nair et al., Journal of Investigative Dermatology 2008⁴⁴ Nair et al., Journal of Investigative Dermatology 2008
Polymorphisms of the IL12B and IL23R genes are associated with psoriasis, a case-control study of 1,810 psoriasis cases and 2,522 controls from North American and German Caucasian cohorts. rs6887695 showed OR 1.49 with p = 2.7×10⁻¹⁵ — one of the most statistically significant associations at the IL12B locus in European populations. Importantly, rs6887695 retained independent association from rs3212227 in haplotype analyses, demonstrating that the two SNPs tag related but non-redundant regulatory effects. The Cargill et al. 2007 AJHG study⁵⁵ Cargill et al. 2007 AJHG study
first large-scale confirmation of IL12B in psoriasis; 1,446 cases + 1,432 controls across three North American cohorts confirmed that rs6887695 and rs3212227 together define a common risk haplotype (OR 1.40) and a protective haplotype (OR 0.58), with the protective haplotype being one of the most statistically robust findings at any psoriasis locus.

A meta-analysis by Zhu et al. 2013⁶⁶ meta-analysis by Zhu et al. 2013
11 studies, Rheumatology International pooled data across European cohorts and reported that the protective G allele (non-risk allele) had OR 0.704 for psoriasis and OR 0.677 for psoriatic arthritis, corresponding to an OR of ~1.42 for the C risk allele for psoriasis and ~1.48 for psoriatic arthritis. These pooled estimates are consistent across studies and confirm that the effect size is in the moderate-to-strong range for a common regulatory variant.

For inflammatory bowel disease, a meta-analysis by Wang et al. 2021⁷⁷ meta-analysis by Wang et al. 2021
17 studies, 9,827 CD cases + 7,583 UC cases + 16,044 controls found the C allele significantly associated with both Crohn's disease (OR 1.17, 95% CI 1.12–1.22) and ulcerative colitis (OR 1.16, 95% CI 1.09–1.23). This confirms the IL12B upstream locus as a shared susceptibility factor for both skin and gut inflammatory disease — consistent with the well-established clinical co-occurrence of psoriasis and IBD.

The association extends to psoriatic arthritis (OR ~1.48 pooled), multiple sclerosis (validated replication in European cohort), ankylosing spondylitis (Chinese Han cohort), and other IL-12/23-driven autoimmune conditions, establishing rs6887695 as a broadly immunologically relevant locus rather than a skin-specific variant.

Practical Actions

For individuals carrying one or two copies of the C allele, the most clinically relevant implications are: (1) moderately elevated lifetime risk for psoriasis, psoriatic arthritis, and inflammatory bowel disease; (2) heightened importance of early symptom recognition across both skin and gut; and (3) pharmacogenomic context for biologic therapy. Because rs6887695 tags the same IL12B regulatory haplotype studied in ustekinumab (anti-p40) pharmacogenomics research, the result is relevant to biologic selection if psoriasis or Crohn's disease develops requiring systemic treatment. The canonical risk haplotype (carrying the C allele at rs6887695 together with the A allele at rs3212227) defines elevated p40 expression — the target of ustekinumab (Stelara), which blocks both IL-12 and IL-23 by neutralizing the shared p40 subunit.

Lifestyle factors that amplify the IL-12/23 axis include streptococcal pharyngitis (a proven psoriasis trigger through Th1 activation), skin trauma (Koebner phenomenon), obesity (adipose tissue-derived cytokines augment IL-23), and smoking (worsens Crohn's disease and psoriasis outcomes). Each of these represents a modifiable amplifier of the genetic baseline this variant establishes.

Interactions

rs6887695 is the upstream member of the canonical IL12B two-SNP psoriasis risk haplotype; rs3212227 (3'-UTR of IL12B) is the other member. The two SNPs tag overlapping but non-redundant regulatory states and are studied together in haplotype analyses. rs12188300 (near-gene IL12B intergenic) and rs3213094 (intronic IL12B) lie in partial linkage disequilibrium with the rs6887695/rs3212227 haplotype and provide additional resolution of IL12B-driven susceptibility. rs11209026 (IL23R R381Q) is the most important pathway modifier: the protective A allele at rs11209026 is a loss-of-function IL-23 receptor variant that attenuates downstream Th17 signaling regardless of p40 production level — individuals carrying both IL12B C risk alleles and the IL23R protective A allele have partially antagonistic genetics where elevated p40 supply is countered by reduced receptor responsiveness.